title: Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
abstract: BACKGROUND
  Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate. We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration.
  
  
  METHODS
  The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3.
  
  
  RESULTS
  High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1.
  
  
  CONCLUSIONS
  These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
authors.affiliation: Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons-Hainaut, Avenue du Champ de Mars 6, Pentagone 1B, B-7000, Mons, Belgium.
authors.forename: Sven
authors.initials: S
authors.lastname: Saussez
authors.forename: Diana-Raluca
authors.initials: DR
authors.lastname: Cucu
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Dominique
authors.initials: D
authors.lastname: Chevalier
authors.forename: Herbert
authors.initials: H
authors.lastname: Kaltner
authors.forename: Sabine
authors.initials: S
authors.lastname: André
authors.forename: Agnes
authors.initials: A
authors.lastname: Wacreniez
authors.forename: Gérard
authors.initials: G
authors.lastname: Toubeau
authors.forename: Isabelle
authors.initials: I
authors.lastname: Camby
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Gabius
authors.forename: Robert
authors.initials: R
authors.lastname: Kiss
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D005260:Female; D037502:Galectin 3 / Q000378:metabolism; D037161:Galectins / Q000378:metabolism*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D037502:Galectin 3; D037161:Galectins; C092525:LGALS7 protein, human